Pharmacological approach to the treatment of long and short QT syndromes
about
Long QT Syndrome: An Emerging Role for Inflammation and ImmunityThe role of late I Na in development of cardiac arrhythmiasModelling the long QT syndrome with induced pluripotent stem cellsDrug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutationEmpirical correlation of triggered activity and spatial and temporal re-entrant substrates with arrhythmogenicity in a murine model for Jervell and Lange-Nielsen syndrome.QT prolongation in the intensive care unit: commonly used medications and the impact of drug-drug interactions.Supplemental studies for cardiovascular risk assessment in safety pharmacology: a critical overview.Potassium-channel mutations and cardiac arrhythmias--diagnosis and therapy.Cardiac potassium channel subtypes: new roles in repolarization and arrhythmia.Modulation of the QT interval duration in hypertension with antihypertensive treatment.Hydrocinnamic Acid Inhibits the Currents of WT and SQT3 Syndrome-Related Mutants of Kir2.1 Channel.Pharmacogenomics and pharmacogenetics for the intensive care unit: a narrative review.Autoimmune channelopathies as a novel mechanism in cardiac arrhythmias.Styrax blocks inward and outward current of Kir2.1 channel.PA-6 inhibits inward rectifier currents carried by V93I and D172N gain-of-function KIR2.1 channels, but increases channel protein expression.Re-trafficking of hERG reverses long QT syndrome 2 phenotype in human iPS-derived cardiomyocytes.Engineered human pluripotent stem cell-derived cardiac cells and tissues for electrophysiological studies.Therapeutic effects of a taurine-magnesium coordination compound on experimental models of type 2 short QT syndrome.
P2860
Q26769710-EEB72AE4-8DF8-4842-ACC1-37838AE62910Q26823149-1E0DC038-84A4-43B3-98B0-1046B54EC826Q29620092-CA1F9E90-E5E7-40ED-BD9A-9039FDF88FAFQ34793218-630B761C-2BED-470E-9159-2A9E59139813Q37286117-05D30B42-537F-4F9B-9383-6BA872B33EF6Q37727223-4345C267-4F62-47E7-AD64-499FDF17770CQ37909132-177A438E-F014-492E-AE16-DFA3FB419AE6Q37980020-1B29DE46-AE86-4657-9CF0-C3FD20CEF8CBQ38201409-AB9D18F6-C9A6-4FB1-A237-F106381D934FQ38383090-8F902632-0C91-42E4-9C5C-3BCFB420BC38Q38703390-E5A24D55-CC8D-4B08-BD86-F63D093D3373Q38983589-A14802AB-C79E-4111-9C21-393350FB514DQ39282353-3B471173-3086-499F-839E-6BC91379C70CQ39474348-83561081-63AA-4B34-9B28-76C9401E809AQ41033530-AB89E3E1-27EC-4CB5-90DC-643A5548BCEAQ42231933-0636B8D8-F216-4289-940C-4E8BFC182E8AQ49455393-26980215-DE49-4EF4-A401-8612C9AD27B2Q50088120-284EA308-73C1-400D-9528-3FB2F02E3C79
P2860
Pharmacological approach to the treatment of long and short QT syndromes
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Pharmacological approach to the treatment of long and short QT syndromes
@ast
Pharmacological approach to the treatment of long and short QT syndromes
@en
type
label
Pharmacological approach to the treatment of long and short QT syndromes
@ast
Pharmacological approach to the treatment of long and short QT syndromes
@en
prefLabel
Pharmacological approach to the treatment of long and short QT syndromes
@ast
Pharmacological approach to the treatment of long and short QT syndromes
@en
P2860
P1476
Pharmacological approach to the treatment of long and short QT syndromes
@en
P2093
Chinmay Patel
P2860
P304
P356
10.1016/J.PHARMTHERA.2008.02.001
P577
2008-04-01T00:00:00Z